These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2284297)

  • 1. The application of response criteria on reporting treatment results in cancer trials.
    Kurth K
    Prog Clin Biol Res; 1990; 359():49-64; discussion 73-4. PubMed ID: 2284297
    [No Abstract]   [Full Text] [Related]  

  • 2. Criteria for evaluating patient responses to treatment modalities for prostatic cancer.
    Slack NH; Murphy GP
    Urol Clin North Am; 1984 May; 11(2):337-42. PubMed ID: 6375069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials.
    Collette L
    Eur Urol; 2008 Jan; 53(1):6-9. PubMed ID: 17764823
    [No Abstract]   [Full Text] [Related]  

  • 4. Size of phase III cancer clinical trials.
    Simon R
    Cancer Treat Rep; 1985 Oct; 69(10):1087-93. PubMed ID: 4042088
    [No Abstract]   [Full Text] [Related]  

  • 5. Cryotherapy for prostate cancer: what we know, what we need to know.
    Theodorescu D
    J Urol; 2008 Aug; 180(2):437-8. PubMed ID: 18550127
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer gene therapy: outcome of basic research and clinical trials.
    Nasu Y; Djavan B; Marberger M; Kumon H
    Tech Urol; 1999 Dec; 5(4):185-90. PubMed ID: 10591255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferred treatment in localized prostatic cancer.
    Smith PH; Armitage TG; Cooper EH
    Prog Clin Biol Res; 1990; 359():191-7; discussion 223-9. PubMed ID: 2284291
    [No Abstract]   [Full Text] [Related]  

  • 8. Design and analysis of prostate cancer trials.
    Sylvester R
    Acta Urol Belg; 1994 Apr; 62(1):23-9. PubMed ID: 8197926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for randomization and stratification and endpoints for the evaluation of trials.
    Sylvester RJ; Suciu S; Yamanaka H
    Prog Clin Biol Res; 1988; 269():275-87. PubMed ID: 3293065
    [No Abstract]   [Full Text] [Related]  

  • 10. Objective response criteria in phase II and phase III studies.
    Jones WG; Akaza H; Van Oosterom AT; Kotake T
    Prog Clin Biol Res; 1988; 269():243-60. PubMed ID: 3293063
    [No Abstract]   [Full Text] [Related]  

  • 11. [Morphological factors in the prognosis of the treatment results in prostatic cancer].
    Murzaliev AD; Iiazaliev KT; Abdyldaev RA; Sizikov AI
    Urol Nefrol (Mosk); 1996; (1):22-5. PubMed ID: 8659037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer vaccine field gets shot of optimism from positive results.
    Brower V
    Nat Med; 2005 Apr; 11(4):360. PubMed ID: 15812502
    [No Abstract]   [Full Text] [Related]  

  • 13. [Survival of metastatic prostate cancer: 71 patients followed for seven to eleven years].
    Prog Urol; 1997 Apr; 7(2):254-8. PubMed ID: 9264768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
    Höltl W; Lunglmayr G
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prostate-specific antigen as an evaluation method in the treatment of hormone-refractory cancer of the prostate].
    Morote J; Lorente JA; Vallejo C; Encabo G; López-Pacios MA; De Torres JA; Soler Rosello A
    Actas Urol Esp; 1994 Jun; 18(6):656-9. PubMed ID: 7524278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues on mortality from prostate cancer: role of clinical trials.
    Horton J
    Prog Clin Biol Res; 1987; 239():797-800. PubMed ID: 3658995
    [No Abstract]   [Full Text] [Related]  

  • 17. Surrogate and mediating endpoints: current status and future directions.
    Prentice RL
    J Natl Cancer Inst; 2009 Feb; 101(4):216-7. PubMed ID: 19211455
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment for hormone-refractory or relapsing prostatic cancer].
    Hirao Y; Ozono S; Okajima E
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for prostate cancer. Early screening is important despite lack of data from trials.
    Catalona WJ
    BMJ; 1997 Jul; 315(7101):187. PubMed ID: 9251561
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate cancer: metastatic.
    Michaelson D; Talcott J; Smith M
    Clin Evid; 2002 Jun; (7):804-11. PubMed ID: 12230706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.